COST-EFFECTIVENESS MODEL OF LEBRIKIZUMAB COMPARED TO DUPILUMAB IN THE TREATMENT OF AUSTRIAN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Schwarz, B. [1 ]
Sole-Feu, L. [2 ]
Akmaz, B. [3 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Almirall SA, Barcelona, Catalonia, Spain
[3] Pricing & Med Affairs Almirall SA, Reinbek, SH, Germany
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE705
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of dupilumab for the treatment of severe atopic dermatitis in adults in Italy
    Costanzo, Antonio
    Furneri, Gianluca
    Bitonti, Rossella
    Pedone, Maria Paola
    Fanelli, Francesca
    Di Turi, Roberta
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2020, 7 (01) : 57 - 65
  • [2] COST-EFFECTIVENESS ANALYSIS OF DUPILUMAB FOR THE TREATMENT OF SEVERE ATOPIC DERMATITIS IN ADOLESCENT AND CHILDREN PATIENTS IN ITALY
    Pedone, M. P.
    Serra, A.
    Bitonti, R.
    Furneri, G.
    VALUE IN HEALTH, 2022, 25 (01) : S42 - S42
  • [3] Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
    Ong, Clarence
    Briones, Jamaica
    Lim, Zhi Zhen
    Chandran, Nisha Suyien
    Lee, Haur Yueh
    Li, Benny Kaihui
    Yew, Yik Weng
    Wee, Hwee-Lin
    PHARMACOECONOMICS-OPEN, 2024, 8 (06) : 809 - 822
  • [4] Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Diana Bernardo
    Thomas Bieber
    Tiago Torres
    American Journal of Clinical Dermatology, 2023, 24 : 753 - 764
  • [5] Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
    Bernardo, Diana
    Bieber, Thomas
    Torres, Tiago
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 753 - 764
  • [6] COST-EFFECTIVENESS ANALYSIS OF DUPILUMAB FOR THE TREATMENT OF ATOPIC DERMATITIS IN ADOLESCENT PATIENTS IN ITALY
    Fanelli, F.
    Pedone, M. P.
    Serra, A.
    Bitonti, R.
    Furneri, G.
    VALUE IN HEALTH, 2020, 23 : S412 - S412
  • [7] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [8] Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective
    Johansson, Erin
    Giovannitti, Massimo
    Mezzetti, Maurizio
    Lu, Na
    Sabatino, Silvia
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1155 - 1166
  • [9] Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective
    Pedone, Maria Paola
    Dobreva, Miryana
    Bastian, Mike
    Tavi, Jules
    Noonan, Kerry
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 800 - 802
  • [10] Dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kraft, Magdalena
    Worm, Margitta
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (04) : 301 - 310
12345